An interventional study of Watch Rx system and Parkinson's Disease Inpatient Clinical Knowledge and Management Program in Parkinson Disease, sponsored by Hackensack Meridian Health. Terminated at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by Hackensack Meridian Health · Not applicable, Interventional, and Supportive care
This study will focus on patients with Parkinson's Disease in the adult inpatient units of Hackensack University Medical Center. We are measuring the effect of a Parkinson's Disease Inpatient Clinical Knowledge and Management Program on adherence to Parkinson's Disease medication using a Parkinson's Disease Identification Wrist Band, smartwatch and medication schedule card
Parkinson's Disease (PD), the second-most common neurodegenerative disorder and is ranked the fourteenth leading cause of death. PD prevalence rate in the United States is estimated to be approximately 0.3% and is ranked the fourteenth leading cause of death (CDC, 2013). Depending on the methodology, the national prevalence data on PD is varied and insufficient. PD is projected to increase by 4% to 5% in age 65 and over 85 years respectively and is associated with a high economic burden exceeding $14.4 billion per year.
Admission to the hospital is identified as a major risk factor due to imprecise timing of medication administration, disruption of sleep pattern, dietary changes, and unfamiliarity of the hospital environment which all contribute to the exacerbation of PD symptoms. Parkinson's disease Foundation, 2015). Hospital length of stay for patients with PD is 1.45 times higher in comparison to non- PD patients.
A study by Chou et al., (2011) involving 51 worldwide National Parkinson Foundation Centers found 94% of centers were not confident in the care and knowledge hospital professionals provided specific to: PD medications, complex drug interactions, contraindications and precise timing of medication administration. Hospital co-morbidities could be improved or prevented by adjustment of PD medication and medication adherence, critical in decreasing hospital length of stay.
The retrospective phase will be a data collection of adult patients admitted with a primary and secondary diagnosis of Parkinson's disease during January - June 2015 (6 month period). There will be 150 patients selected by the principal investigator(s) from chart review. In addition, the clinicians chosen for the study will complete a Parkinson's Disease Knowledge Assessment Survey.
The prospective phase will begin after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program for staff nurses, advanced practice nurses (APN), nursing assistants, patient care technicians, case managers, adult inpatient physician assistants, pharmacists, occupational therapists, physical therapists, nurse educators, and dietitians. There will be 150 patients selected from the adult inpatient units by the principal investigator(s) that meet the inclusion criteria and confirm through an informed consent that they will participate in the study.
The selected patients will be registered in a WatchRx interface via website URL by the Principal Investigator(s) and the Transition of Care(TC) Pharmacist and required to wear a Watch Rx smartwatch for the duration of their hospitalization. The Watch Rx Interface will store all medical information, necessary treatments, and daily clinical care for the patient which is synchronized to the smartwatch on the patient's wrist. The smartwatch will send alerts to the patient's assigned nurse's iPad through a Watch Rx app for medication administration, missed PD medications, battery conditions, and enables messaging between the primary nurse and the patient.
The WatchRx smartwatch will remind when it is time to take the medication. If the Parkinson's Disease medication is not administered, it sends missed medication reminder alerts to the nurse. For fixed time medication, the reminder is every 3 minutes up to 10 minutes.
During the prospective phase, the research team will collect data from multiple sources such as the Watch Rx system, EPIC Hyperspace, and Case Report forms over a 6 month study period. The data will be calculated by using statistical analysis for the continuous variables and categorical variables identified from the collection of data. All study data will be imported into SAS software where data programming will be utilized to flag and generate queries on out-of-range data issues until they are resolved. All analysis will be performed using SAS version 9.4 (SAS Institute Inc. Cary, North Carolina, USA Data will be handled in a confidential manner to meet mandated IT Security standards and to prevent loss of privacy. All electronic files will be stored in an encrypted and password-protected database on a secure medical center server. Only co-investigators, advanced practice nurses, and the data coordinator who contact the subjects will have access to information linked to subject identifiers.
This study will improve timely administration of medications to PD patients. Patients enrolled in the study will have direct monitoring of their medication compliance and adherence. Patients participating in the registry will be gain information from the current research and possibly create a support group amongst themselves. This study will improve knowledge of Parkinson's disease amongst clinicians and better medication management of PD patients
4,583 studies on the registry are indexed under Parkinson Disease; 1,097 are open to participants now.
This study's enrollment of 477 is above the median of 40 across 3,365 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Hackensack Meridian Health is the lead sponsor of 113 studies on the registry; 28 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with Parkinson disease before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
Device: Watch Rx system
Patients after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program who are also assigned to a WatchRx system
Device: Watch Rx system · Other: Parkinson's Disease Inpatient Clinical Knowledge and Management Program
Clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
Other: Parkinson's Disease Inpatient Clinical Knowledge and Management Program
Clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
Other: Parkinson's Disease Inpatient Clinical Knowledge and Management Program
The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
Clinician's Parkinson's Disease Knowledge Assessment Survey Scores
Clinician's Parkinson's Disease Knowledge Assessment Survey scores before and after the Parkinson's Disease Inpatient Clinical Knowledge and Management Program. A 20-question survey was administered to PD clinicians for a group measurement of PD knowledge. Scores ranged from 0 - 100% and reflected the percentage of clinicians who correctly answered the question. If 70% or more clinicians correctly answered the question, the group was considered knowledgeable on that topic; if \<70% of clinicians responded incorrectly, they were considered not knowledgeable on the information that the question assessed. Survey questions addressed three PD areas: 1) medication/treatment, 2) symptoms/diagnosis, and 3) epidemiology/pathophysiology.
Time frame: 6 months
Number of PD Medications Administered on Time (15 Minute Window)
The number of Parkinson's Disease (PD) medications administered within the 15-minute timeframe at baseline
Time frame: within 15 minutes post PD medication administration time
Number of Patients With Contraindicated Medications Administered.
Measure the number of patients who were adminstered contraindicated medications
Time frame: 6 months
Number Patients With Falls, Falls With Injury, Positive CAM/Mini-cog
The number of falls, number of falls with injury, and number of patients with positive Confusion Assessment Method (CAM)/Mini-Cog scores) in hospitalized patients. Mini-cog is performed on all admitted patients 65 years and older and is a quick screening for "cognitive vital sign" and early dementia detection. The scale classifies patients as being positive or negative for dementia. The Confusion Assessment Method (CAM) is performed on all adult admissions at the time of admission with reporting 1) every shift if the first test is positive, or 2) daily if the first test is negative. It improves the detection and recognition of delirium accurately and quickly in clinical and research settings. CAM is documentation of observed patient behavior during brief, structured interviews according to classification of positive or negative for dementia. There are no numerical (minimum or maximum) values assigned.
Time frame: 6 Months
Length of Stay in Hospitalized Parkinson's Disease Patients.
Average length of stay in hospitalized Parkinson's Disease patients
Time frame: 6 months
Number of PD Medications Administered on Time (Within 15 Minute Window)
Track the difference that the WatchRx system has on scheduled PD medication administration time versus actual PD medication administration time
Time frame: 15 minutes post assigned medication administration time.
Number of PD Medication Errors After Using the WatchRX System
The number of contraindicated medications administered to Parkinson's disease patients after using the WatchRX system
Time frame: 6 Months
Number of Falls, Falls Within Injury, Positive CAM Scores, and Positive Mini-Cog Scores After Using the WatchRX System
The number of falls, number of falls with injury, number of positive CAM scores, and number of positive Mini-Cog scores after using the WatchRX system.
Time frame: 6 months
Length of Stay With the WatchRx System
Parkinson's disease patients' length of stay after using the WatchRx system
Time frame: 6 months
| Milestone | Retrospective Phase | Prospective Phase-Watch Rx System | Retrospective Phase - Clinicians | Prospective Phase - Clinicians |
|---|---|---|---|---|
| Started | 131 | 0 | 266 | 80 |
| Completed | 131 | 0 | 266 | 80 |
| Not completed | 0 | 0 | 0 | 0 |
Clinician's Parkinson's Disease Knowledge Assessment Survey scores before and after the Parkinson's Disease Inpatient Clinical Knowledge and Management Program. A 20-question survey was administered to PD clinicians for a group measurement of PD knowledge. Scores ranged from 0 - 100% and reflected the percentage of clinicians who correctly answered the question. If 70% or more clinicians correctly answered the question, the group was considered knowledgeable on that topic; if \<70% of clinicians responded incorrectly, they were considered not knowledgeable on the information that the question assessed. Survey questions addressed three PD areas: 1) medication/treatment, 2) symptoms/diagnosis, and 3) epidemiology/pathophysiology.
| average knowledge score | Clinicians' Knowledge Before Educational Intervention | Clinicians' Knowledge After Educational Intervention |
|---|---|---|
| Clinician's Parkinson's Disease Knowledge Assessment Survey Scores | 68.50 (0 to 100) | 78.75 (0 to 100) |
The number of Parkinson's Disease (PD) medications administered within the 15-minute timeframe at baseline
| number of PD meds administered in 15 min | Retrospective Patient Outcomes |
|---|---|
| Number of PD Medications Administered on Time (15 Minute Window) | 678 |
Measure the number of patients who were adminstered contraindicated medications
| Participants | Retrospective Patient Outcomes |
|---|---|
| Number of Patients With Contraindicated Medications Administered. | 21 |
The number of falls, number of falls with injury, and number of patients with positive Confusion Assessment Method (CAM)/Mini-Cog scores) in hospitalized patients. Mini-cog is performed on all admitted patients 65 years and older and is a quick screening for "cognitive vital sign" and early dementia detection. The scale classifies patients as being positive or negative for dementia. The Confusion Assessment Method (CAM) is performed on all adult admissions at the time of admission with reporting 1) every shift if the first test is positive, or 2) daily if the first test is negative. It improves the detection and recognition of delirium accurately and quickly in clinical and research settings. CAM is documentation of observed patient behavior during brief, structured interviews according to classification of positive or negative for dementia. There are no numerical (minimum or maximum) values assigned.
| Participants | Retrospective Patient Outcomes |
|---|---|
| Number of falls | 1 |
| Number of falls with injury | 0 |
| Number of patients with positive CAM scores | 47 |
| Number of patients with abnormal mini-cog scores | 45 |
Average length of stay in hospitalized Parkinson's Disease patients
| days | Retrospective Patient Outcomes |
|---|---|
| Length of Stay in Hospitalized Parkinson's Disease Patients. | 6.1 ± 6.6 |
Track the difference that the WatchRx system has on scheduled PD medication administration time versus actual PD medication administration time
No measurements were reported for this outcome.
The number of contraindicated medications administered to Parkinson's disease patients after using the WatchRX system
No measurements were reported for this outcome.
The number of falls, number of falls with injury, number of positive CAM scores, and number of positive Mini-Cog scores after using the WatchRX system.
No measurements were reported for this outcome.
Parkinson's disease patients' length of stay after using the WatchRx system
No measurements were reported for this outcome.
Collected over Up to 6 months for patient and clinician participants in the Retrospective Phase. Duration of the educational intervention including pre and post-surveys for clinicians in the Prospective Phase, overall duration 5 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Retrospective Phase - Watch Rx System | 0/131 (0%) | 0/131 (0%) | 0/131 (0%) |
| Prospective Phase - Watch Rx System | — | — | — |
| Retrospective Phase - Clinicians | 0/266 (0%) | 0/266 (0%) | 0/266 (0%) |
| Prospective Phase - Clinicians | 0/80 (0%) | 0/80 (0%) | 0/80 (0%) |
No one was enrolled in the patient prospective phase.
| Age, Customized(years) | Retrospective Phase | Prospective Phase-Watch Rx System | Total |
|---|---|---|---|
| Mean | 76 ± 14.4 | — | 76 ± 14.4 |
| Sex: Female, Male(Participants) | Retrospective Phase | Prospective Phase-Watch Rx System | Total |
|---|---|---|---|
| Female | 54 | 0 | 54 |
| Male | 77 | 0 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Retrospective Phase | Prospective Phase-Watch Rx System | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 0 | 23 |
| Not Hispanic or Latino | 107 | 0 | 107 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Retrospective Phase | Prospective Phase-Watch Rx System | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 0 | 4 |
| White | 106 | 0 | 106 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 17 | 0 | 17 |
| Region of Enrollment(participants) | Retrospective Phase | Prospective Phase-Watch Rx System | Total |
|---|---|---|---|
| United States | 131 | — | 477 |
Documents are hosted by the registry — open the source record to download them.
Ran from Aug 2018 to primary completion in Jan 2022, 41 months.
Results were first posted in Mar 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.